8355 related articles for article (PubMed ID: 19649202)
1. Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations.
Ciuffreda L; Del Bufalo D; Desideri M; Di Sanza C; Stoppacciaro A; Ricciardi MR; Chiaretti S; Tavolaro S; Benassi B; Bellacosa A; Foà R; Tafuri A; Cognetti F; Anichini A; Zupi G; Milella M
Neoplasia; 2009 Aug; 11(8):720-31. PubMed ID: 19649202
[TBL] [Abstract][Full Text] [Related]
2. MEK inhibitor PD0325901 significantly reduces the growth of papillary thyroid carcinoma cells in vitro and in vivo.
Henderson YC; Chen Y; Frederick MJ; Lai SY; Clayman GL
Mol Cancer Ther; 2010 Jul; 9(7):1968-76. PubMed ID: 20587665
[TBL] [Abstract][Full Text] [Related]
3. BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines.
Leboeuf R; Baumgartner JE; Benezra M; Malaguarnera R; Solit D; Pratilas CA; Rosen N; Knauf JA; Fagin JA
J Clin Endocrinol Metab; 2008 Jun; 93(6):2194-201. PubMed ID: 18381570
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for "vertical" and "lateral" combination strategies.
Ricciardi MR; Scerpa MC; Bergamo P; Ciuffreda L; Petrucci MT; Chiaretti S; Tavolaro S; Mascolo MG; Abrams SL; Steelman LS; Tsao T; Marchetti A; Konopleva M; Del Bufalo D; Cognetti F; Foà R; Andreeff M; McCubrey JA; Tafuri A; Milella M
J Mol Med (Berl); 2012 Oct; 90(10):1133-44. PubMed ID: 22399013
[TBL] [Abstract][Full Text] [Related]
5. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner.
Joseph EW; Pratilas CA; Poulikakos PI; Tadi M; Wang W; Taylor BS; Halilovic E; Persaud Y; Xing F; Viale A; Tsai J; Chapman PB; Bollag G; Solit DB; Rosen N
Proc Natl Acad Sci U S A; 2010 Aug; 107(33):14903-8. PubMed ID: 20668238
[TBL] [Abstract][Full Text] [Related]
6. Potent inhibition of thyroid cancer cells by the MEK inhibitor PD0325901 and its potentiation by suppression of the PI3K and NF-kappaB pathways.
Liu D; Xing M
Thyroid; 2008 Aug; 18(8):853-64. PubMed ID: 18651802
[TBL] [Abstract][Full Text] [Related]
7. Mek inhibition results in marked antitumor activity against metastatic melanoma patient-derived melanospheres and in melanosphere-generated xenografts.
Sette G; Fecchi K; Salvati V; Lotti F; Pilozzi E; Duranti E; Biffoni M; Pagliuca A; Martinetti D; Memeo L; Milella M; De Maria R; Eramo A
J Exp Clin Cancer Res; 2013 Nov; 32(1):91. PubMed ID: 24238212
[TBL] [Abstract][Full Text] [Related]
8. 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography is a sensitive method for imaging the response of BRAF-dependent tumors to MEK inhibition.
Solit DB; Santos E; Pratilas CA; Lobo J; Moroz M; Cai S; Blasberg R; Sebolt-Leopold J; Larson S; Rosen N
Cancer Res; 2007 Dec; 67(23):11463-9. PubMed ID: 18056475
[TBL] [Abstract][Full Text] [Related]
9. MAPK pathway inhibition induces MET and GAB1 levels, priming BRAF mutant melanoma for rescue by hepatocyte growth factor.
Caenepeel S; Cooke K; Wadsworth S; Huang G; Robert L; Moreno BH; Parisi G; Cajulis E; Kendall R; Beltran P; Ribas A; Coxon A; Hughes PE
Oncotarget; 2017 Mar; 8(11):17795-17809. PubMed ID: 28147313
[TBL] [Abstract][Full Text] [Related]
10. BRAF mutation predicts sensitivity to MEK inhibition.
Solit DB; Garraway LA; Pratilas CA; Sawai A; Getz G; Basso A; Ye Q; Lobo JM; She Y; Osman I; Golub TR; Sebolt-Leopold J; Sellers WR; Rosen N
Nature; 2006 Jan; 439(7074):358-62. PubMed ID: 16273091
[TBL] [Abstract][Full Text] [Related]
11. The MAPK pathway as an apoptosis enhancer in melanoma.
Haydn JM; Hufnagel A; Grimm J; Maurus K; Schartl M; Meierjohann S
Oncotarget; 2014 Jul; 5(13):5040-53. PubMed ID: 24970815
[TBL] [Abstract][Full Text] [Related]
12. RAF265 inhibits the growth of advanced human melanoma tumors.
Su Y; Vilgelm AE; Kelley MC; Hawkins OE; Liu Y; Boyd KL; Kantrow S; Splittgerber RC; Short SP; Sobolik T; Zaja-Milatovic S; Dahlman KB; Amiri KI; Jiang A; Lu P; Shyr Y; Stuart DD; Levy S; Sosman JA; Richmond A
Clin Cancer Res; 2012 Apr; 18(8):2184-98. PubMed ID: 22351689
[TBL] [Abstract][Full Text] [Related]
13. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory effects of the mitogen-activated protein kinase kinase inhibitor CI-1040 on the proliferation and tumor growth of thyroid cancer cells with BRAF or RAS mutations.
Liu D; Liu Z; Jiang D; Dackiw AP; Xing M
J Clin Endocrinol Metab; 2007 Dec; 92(12):4686-95. PubMed ID: 17911174
[TBL] [Abstract][Full Text] [Related]
15. BRAF mutation-selective inhibition of thyroid cancer cells by the novel MEK inhibitor RDEA119 and genetic-potentiated synergism with the mTOR inhibitor temsirolimus.
Liu D; Xing J; Trink B; Xing M
Int J Cancer; 2010 Dec; 127(12):2965-73. PubMed ID: 21351275
[TBL] [Abstract][Full Text] [Related]
16. Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.
Nissan MH; Pratilas CA; Jones AM; Ramirez R; Won H; Liu C; Tiwari S; Kong L; Hanrahan AJ; Yao Z; Merghoub T; Ribas A; Chapman PB; Yaeger R; Taylor BS; Schultz N; Berger MF; Rosen N; Solit DB
Cancer Res; 2014 Apr; 74(8):2340-50. PubMed ID: 24576830
[TBL] [Abstract][Full Text] [Related]
17. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
[TBL] [Abstract][Full Text] [Related]
18. Fisetin, a phytochemical, potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells.
Pal HC; Baxter RD; Hunt KM; Agarwal J; Elmets CA; Athar M; Afaq F
Oncotarget; 2015 Sep; 6(29):28296-311. PubMed ID: 26299806
[TBL] [Abstract][Full Text] [Related]
19. Cytokines can counteract the inhibitory effect of MEK-i on NK-cell function.
Manzini C; Venè R; Cossu I; Gualco M; Zupo S; Dono M; Spagnolo F; Queirolo P; Moretta L; Mingari MC; Pietra G
Oncotarget; 2016 Sep; 7(38):60858-60871. PubMed ID: 27563819
[TBL] [Abstract][Full Text] [Related]
20. Curcumin-induced antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of IkappaB kinase and nuclear factor kappaB activity and are independent of the B-Raf/mitogen-activated/extracellular signal-regulated protein kinase pathway and the Akt pathway.
Siwak DR; Shishodia S; Aggarwal BB; Kurzrock R
Cancer; 2005 Aug; 104(4):879-90. PubMed ID: 16007726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
